Navigation Links
Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board
Date:4/20/2009

Renowned Physicians Join World Class Group of Advisors

SAN DIEGO, April 20 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the expansion of its Clinical Advisory Board, naming Donald H. Batts, MD, FACP, FIDSA, and G. Ralph Corey, MD, as the sixth and seventh members of the group of anti-infective thought leaders. Dr. Batts is a Professor of Medicine at Michigan State University and the Chief of Infectious Diseases at its Kalamazoo Campus. Dr. Corey is the Gary Hock Distinguished Professor of Global Health and the Director of the Hubert/Yeargan Center for Global Health and Director of Infectious Disease Research at the Duke Clinical Research Institute.

"Don and Ralph bring years of academic and industry experience to the Advisory Board that will benefit us as we advance torezolid into Phase 3 development," said Philippe Prokocimer, MD, Chief Medical Officer of Trius. "Collectively, their clinical development of anti-infectives has contributed to the approval of several important new drugs."

"Torezolid is one of the most compelling antibacterial drugs in the clinic so I look forward to advising Trius on its continued development," said Dr. Batts, who was lead investigator at the Upjohn Company for the development of linezolid, the sole marketed antibiotic in the oxazolidinone class.

"I look forward to working closely with Dr. Prokocimer and the rest of the Trius team to help develop the clinical and regulatory strategy for torezolid as it moves into Phase 3 testing," said Dr. Corey.

"The guidance that these distinguished clinicians provide will be critical not only for torezolid as it transitions into Phase 3 testing, but also for our preclinical programs as we advance them toward Phase 1 testing," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "Our goal is to provide patients and physicians best-in-class therapeutic options to address the growing unmet need for safe and effective treatments for drug resistant bacterial infections in the hospital and in the community."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has licensed worldwide rights outside of Korea to torezolid from Dong-A Pharmaceuticals. Trius' pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Trius Awarded $28 Million Contract to Develop Novel Antibiotics
2. Trius Appoints Paul Truex to Board of Directors
3. Ventus Medical Appoints John McCutcheon as President and CEO
4. Sinobiopharma, Inc. Appoints New Director of Marketing
5. Yongye Biotechnology Appoints New Chief Financial Officer
6. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
7. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
8. BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer
9. MacroGenics Appoints New Vice President of Business Development
10. DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors
11. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... PhUSE will build on the huge success ... Day Events (SDE) to organize a multiple-day US conference. The first annual US ... the pharmaceutical and life sciences industry will cover industry standards, data science, regulations ...
(Date:12/2/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 01, 2016 , ... ... clinical research is through industry-wide collaboration, standardization and a beautiful technology experience. All three ... which convened more than 100 clinical trial leaders from over 40 sponsor, CRO and ...
(Date:12/2/2016)... ... December 02, 2016 , ... The ... to collaboratively developing improved chemistry, manufacturing and control technologies for the pharmaceutical ... with robust, probe-based sampling. , Online liquid chromatography analysis is becoming ...
(Date:12/2/2016)... YORK , Dec. 1, 2016   SurePure, ... photopurification, announced today that the Company has concluded an ... the right for a 90-day period to acquire units ... value of approximately USD 3.7 million.  ... agreement with Tamarack under which Tamarack will seek regulatory ...
Breaking Biology Technology:
(Date:11/15/2016)... DUBLIN , Nov 15, 2016 Research ... - Global Forecast to 2021" report to their offering. ... ... reach USD 16.18 Billion by 2021 from USD 6.21 Billion in ... Growth of the bioinformatics market is driven by ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
Breaking Biology News(10 mins):